ABSTRACT
Background: Gonadotropin-releasing hormone agonists [GnRH-a] was increasingly used for triggering oocyte maturationfor the prevention of ovarian hyperstimulation syndrome. Studies suggest that GnRH-a might be used as a better trigger agent since it causes both Luteinizing hormone and follicle stimulating hormone release from a physiologic natural cycle
Objective: The aim of this study was to evaluate the effect of dual-triggering in assisted reproductive technology outcomes
Materials and Methods: 192 normal responder women aged
Results: The mean of retrieved oocytes and obtained embryos were statistically higher in the dual-trigger group [group I], but the implantation and pregnancy rates were similar in two groups
Conclusion: The results of our study did not confirm the favorable effect of dual-triggered oocyte maturation with a GnRH-a and a standard dosage of hCG as an effective strategy to optimize pregnancy outcome for normal responders in GnRH-antagonist cycles. We think that this new concept requires more studies before becoming a universal controlled ovarian hyperstimulation protocol in vitro fertilization practice
Subject(s)
Humans , Female , Adult , Gonadotropin-Releasing Hormone/agonists , Chorionic Gonadotropin/pharmacology , Reproductive Techniques, Assisted , Single-Blind MethodABSTRACT
Background: Embryo implantation process is a complex phenomenon and depends on fetal and maternal factors interaction. Endometrial thickness is needed for successful implantation
Objective: We designed this study in order to assess adding human chorionic gonadotropin [HCG] to the conventional protocol in endometrial preparation in women with thin endometrium and a history of in vitro fertilization-embryo transfer [IVF-ET] failure
Materials and Methods: The non-randomized clinical trial study [quasi experimental design] was performed on 28 patients. Participants were women who were candidate for frozen-thawed [ET] and had two previous failed ET cycles because of thin endometrial. HCG was administrated [150 IU, intramuscular] from the 8th day of cycle and when endometrial thickness reached at least 7mm HCG was discontinued and frozen thawed ET was done
Results: Totally 28 patients were included. The mean +/- SD age of participants was 30.39 +/- 4.7. The mean of endometrium thickness before and after HCG were 5.07 +/- 0.43 and 7.85 +/- 0.52, respectively p<0.001. Also, there were five clinically and chemically pregnant women
Conclusion: The findings of the study suggested that adding HCG to the conventional preparation method was an effective protocol and significantly improved endometrial thickness and pregnancy outcomes in women with previous embryo transfer failure because of thin endometrium
ABSTRACT
Background: gonadotropin-releasing hormone [GnRH] plays essential roles in embryo implantation, invasion of trophoblastic tissue, and steroid synthesis in the placenta
Objective: the aim of this study was to evaluate the effect of GnRH antagonist administration on pregnancy outcomes in early implantation period
Materials and Methods: in this retrospective study, 94 infertile women undergoing GnRH antagonist protocol who were at risk of ovarian hyperstimulation syndrome [OHSS] were included. Sixty-seven patients [group I] received Cetrorelix 0.25 mg/daily in the luteal phase for 3 days while in 27 participants [group II], it was not administered. Pregnancy outcomes were assessed based on chemical and clinical pregnancy rates
Results: the pregnancy outcomes were not significantly different between two groups [p=0.224]
Conclusion: the present study proposed that luteal phase GnRH antagonist administration does not influence the chance of successful pregnancy outcomes
ABSTRACT
Background: Although pregnancy rate in in vitro fertilization-embryo transfer [IVF-ET] cycles has been increased over the preceding years, but the majority of IVF-ET cycles still fail. Granulocyte colony stimulating factor [GCSF] is a glycoprotein that stimulates cytokine growth factor and induces immune system which may improve pregnancy rate in women with history of implantation failure
Objective; The aim of this study was to evaluate GCSF ability to improve pregnancy rate in women with history of implantation failure
Materials and Methods: 0.5 ml [300 microg/ml[ GCSF was infused intrauterine in intervention group. Pregnancy outcomes were assessed based on clinical pregnancy
Results: The mean age of participants was 31.9S+/-4.71 years old. There were no significant differences between demographic characteristics in two groups [p>0.05]. The pregnancy outcome in GCSF group was improved significantly [p=0.043]
Conclusion: GCSF can improve pregnancy outcome in patients with history of implantation failure
ABSTRACT
There is no doubt that luteal phase support is essential to enhance the reproductive outcome in IVF cycles. In addition to progesterone and human chorionic gonadotropin, several studies have described GnRH agonists as luteal phase support to improve implantation rate, pregnancy rate and live birth rate, whereas other studies showed dissimilar conclusions. All of these studies have been done in fresh IVF cycles. To determine whether an additional GnRH agonist administered at the time of implantation for luteal phase support in frozen-thawed embryo transfer [FET] improves the embryo developmental potential. This is a prospective controlled trial study in 200 FET cycles, patients were randomized on the day of embryo transfer into group 1 [n=100] to whom a single dose of GnRH agonist [0.1 mg triptorelin] was administered three days after transfer and group 2 [n=100], who did not receive agonist. Both groups received daily vaginal progesterone suppositories plus estradiol valerate 6 mg daily. Primary outcome measure was clinical pregnancy rate. Secondary outcome measures were implantation rate, chemical, ongoing pregnancy rate and abortion rate. A total of 200 FET cycles were analyzed. Demographic data and embryo quality were comparable between two groups. No statistically significant difference in clinical and ongoing pregnancy rates was observed between the two groups [26% versus 21%, p=0.40 and 21% versus 17%, p=0.37, respectively]. Administration of a subcutaneous GnRH agonist at the time of implantation does not increase clinical or ongoing pregnancy